The AI model, called AlphaProteo, can design targeted protein binders, promising breakthroughs in cancer treatments and diseases like diabetes.
The tiny DNA-based robots target and destroy diseased cells while sparing healthy tissue.
The Abu Dhabi-based company hopes to treat idiopathic pulmonary fibrosis, and has 30 more drugs in the pipeline.
The health-tech company will use the funding to continue its global disruption of the supplements market.
According to CEO Noor Siddiqui, the company isn’t on a mission to make designer babies, but aims to beat genetic odds and relieve suffering.
A recent Korean report reveals the model numbers of the new health tracking device, as well as details of its key features.
amplifAI Health and Healthspan Digital have joined forces to introduce AI-driven precision vascular age analysis for the MENA region and beyond.
The venture will offer Whole Genome Sequencing in Jordan, Oman, and Iraq, with Saudi Arabia to follow.
The wearable is currently in the prototype stage, with mass production slated to commence in the second quarter of 2024.
![meta[bolic] and oura partner to manage metabolic disease](https://techmgzn.com/wp-content/uploads/2024/01/metabolic-and-oura-partner-to-manage-metabolic-disease-1000x600.jpg)
![meta[bolic] and oura partner to manage metabolic disease](https://techmgzn.com/wp-content/uploads/2024/01/metabolic-and-oura-partner-to-manage-metabolic-disease-400x240.jpg)
![meta[bolic] and oura partner to manage metabolic disease](https://techmgzn.com/wp-content/uploads/2024/01/metabolic-and-oura-partner-to-manage-metabolic-disease-80x80.jpg)
The hybrid therapeutics company will incorporate the smart ring into its programming, taking an innovative approach to care delivery.
